OnCall

In this episode, the first of our Biosimilars series, Brian Biehn, Senior Director of Biosimilar Injectables, and Connor Nell, Director of Commercialization Injectables discuss Biosimilars 101 and resources to utilize to stay better informed.Our next episode will feature information on the current Biosimilar landscape and what we can expect to see in the market. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the eleventh of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses drug pricing and shortages.If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the tenth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses transparency in the House, competition, and lower costs on drugs and services.Our next episode will feature information on drug pricing and shortages. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the ninth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses health issues around Medicare physician payment, and PBM reform.Our next episode will feature information on transparency in the House, competition, and lower costs on drugs and services. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the eighth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses MPFS, Medicare Drug Price Negotiations, PBM reform, and elections.That's all for this episode of OnCall. Our next episode will feature information on politics and policy, and physician payment issues. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the seventh of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses Congress and the fiscal backdrop.Our next episode will feature information on issues regarding MPFS, Medicare Drug Price Negotiations, PBM reform, and elections. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the sixth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses the new DEA proposed rules on prescribing controlled substances and treatments.Our next episode will feature information on payment updates for Medicare. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the fifth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses the End of the Public Health Emergency and what it means for practices.Our next episode will feature information on the New DEA proposed rules on prescribing controlled substances and treatments. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the fourth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses federal budget and debt negotiations and the implications for Medicare, Medicaid and ACA.Our next episode will feature information on the end of the Public Health Emergency and what it means for practices. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the third of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss the Inflation Reduction Act, PBM reform, and 2023 regulations.Our next episode will feature information on federal budget and debt negotiations and the implications for Medicare, Medicaid and ACA. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the second of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss drug coverage, pricing, and payment.Our next episode will feature information on the Inflation Reduction Act, PBM reform, and 2023 regulations. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this episode, the first of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss three important policy trends impacting physicians: Medicare payments, drugs/biologics, and disparities/SDOH.Our next episode will feature information on drug coverage, pricing, and payments. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.

In this Amgen sponsored podcast, David R. Braxton, MD, Chief of Service for Molecular Pathology at Hoag Hospital, shares his insights as considerations on operationalizing biomarker testing into clinical practice in NSCLC. He discusses considerations on improving the turnaround time of test results, clinical application of ctDNA testing as well as strategies for documentation of results for ease of retrieval. Sponsored by Amgen

In this episode, the fifth of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about operationalizing biosimilars into practice and the differences and similarities of this process for biosimilars versus their counterparts. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the fourth of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about the role of the payer in relation to biosimilars, the formulary management process and the differences in treatment of biosimilars by Medicaid and Medicare. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the third of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about the FDA approval process for biosimilars, the Biologics Price Competition and Innovation Act and safety issues or adverse effects related to biosimilar use. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the second of our biosimilar education series, Kathy Oubre, CEO of Pontchartrain Cancer Center, and Neil Udovich, Vice President of Sales for AmerisourceBergen Specialty GPOs, discuss the history of biosimilars, the reception of them in the medical community and their road ahead. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, the first of our biosimilar education series, Kathy Oubre, CEO of Pontchartrain Cancer Center, and Neil Udovich, Vice President of Sales for AmerisourceBergen Specialty GPOs, discuss what biosimilars are (and aren’t), interchangeability with their reference products, and Kathy’s experience with adopting them into her practice.If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com. 

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the importance of emerging biomarkers to basket and umbrella trial designs.If you have any questions for today’s guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the advantages and disadvantages of liquid biopsies to the benefits of ordering test panels.If you have any questions for today’s guest or have a topic you would like to learn more about, email us at OnCallGPO@gmail.com.The content and information contained in this podcast is sponsored by Elevation Oncology. This podcast is for educational, and informational purposes only. This podcast does not constitute medical or other professional advice or services. No person should act or refrain from acting on the basis of content provided in any podcast or website without first seeking appropriate medical advice and counseling. The opinions expressed in this podcast are the opinions of the individual and may not reflect the opinions of IntrinsiQ or Elevation Oncology.